Changes in survival of patients with non–small cell lung cancer in Japan: An interrupted time series study

The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) gefitinib and erlotinib were approved for metastatic or relapsed non–small cell lung cancer (NSCLC) in Japan in 2002 and 2007, respectively. EGFR mutation testing was also approved in 2007. Although clinical trials showed ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniyama, Yukari, Oze, Isao, Koyanagi, Yuriko N., Kawakatsu, Yukino, Ito, Yuri, Matsuda, Tomohiro, Matsuo, Keitaro, Mitsudomi, Tetsuya, Ito, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986076/
https://www.ncbi.nlm.nih.gov/pubmed/36369880
http://dx.doi.org/10.1111/cas.15646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986076/
https://www.ncbi.nlm.nih.gov/pubmed/36369880
http://dx.doi.org/10.1111/cas.15646

Ejemplares similares